NCT05947747View on ClinicalTrials.gov

Safety and Efficacy of EXO-CD24 in Preventing Clinical Deterioration in Patients With Mild-Moderate ARDS

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 4, 2023

Primary Completion Date

December 20, 2025

Study Completion Date

December 20, 2025

Conditions
ARDS
Interventions
DRUG

EXO-CD24

Twice a day for 5 days, dose 10\^10

OTHER

Placebo

Twice a day for 5 days

Trial Locations (1)

64239

RECRUITING

Tel-Aviv Sourasky Medical Center, Tel Aviv

Sponsors

Lead Sponsor

Nano24med
All Listed Sponsors
lead

Nano24med

OTHER

NCT05947747 - Safety and Efficacy of EXO-CD24 in Preventing Clinical Deterioration in Patients With Mild-Moderate ARDS | Biotech Hunter | Biotech Hunter